Athira Pharma, Inc. (ATHA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Athira Pharma reported revenue of $0. Net income was -$105.6M, or -$24.70 per diluted share. Operating activities generated -$45.7M of cash, leaving -$45.8M of free cash flow. At fiscal year end, Athira Pharma held $92.2M in total assets against $64.4M in total liabilities, including $69.3M of cash and equivalents.
Open the full interactive Athira Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Athira Pharma Key Stats
| Share Price | $6.43 |
|---|---|
| Market Cap | $152.6M |
| 52-Week Range | $2.87 – $11.68 |
| Shares Outstanding | 23.7 million (basic, 2026 Q2) |
Athira Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | — | — | $104.0M | $125.5M | $100.9M | $102.3M |
| Gross Profit | — | — | -$104.0M | -$125.5M | -$100.9M | -$102.3M |
| Operating Income | -$20.0M | -$64.0M | -$104.0M | -$125.5M | -$100.9M | -$102.3M |
| Pre-Tax Income | -$20.0M | -$54.9M | -$95.6M | -$117.7M | -$96.9M | -$105.6M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$20.0M | -$54.9M | -$95.6M | -$117.7M | -$96.9M | -$105.6M |
| Diluted EPS | -$16.70 | -$14.90 | -$25.30 | -$30.90 | -$25.20 | -$24.70 |
Athira Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.6M | -$82.9M | -$32.9M | -$19.0M |
| Diluted EPS | -$1.68 | -$19.39 | -$1.73 | -$0.80 |
Athira Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $60.6M | $110.5M | $96.0M | $90.6M | $48.4M | $69.3M |
| Current Assets | $192.3M | $260.8M | $207.5M | $154.7M | $54.8M | $89.5M |
| Total Assets | $279.6M | $332.0M | $258.2M | $160.2M | $58.8M | $92.2M |
| Current Liabilities | $4.4M | $9.3M | $21.4M | $28.8M | $13.1M | $47.5M |
| Total Liabilities | $5.3M | $10.9M | $23.0M | $30.1M | $13.9M | $64.4M |
| Shareholders' Equity | $274.3M | $321.1M | $235.1M | $130.2M | $44.8M | $27.8M |
Athira Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$24.1M | -$43.1M | -$72.5M | -$100.8M | -$97.2M | -$45.7M |
| Cash From Investing | -$210.1M | -$4.1M | $57.7M | $95.1M | $54.8M | -$15.9M |
| Cash From Financing | $292.8M | $97.1M | $654,000 | $493,000 | $194,000 | $82.5M |
| Free Cash Flow | -$26.4M | -$44.7M | -$73.6M | -$101.1M | -$97.2M | -$45.8M |
Figures from Athira Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Athira Pharma financials page for every line item.
Athira Pharma Company Profile
| Ticker | ATHA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Bothell, Washington |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001620463 |
Frequently Asked Questions
What was Athira Pharma's revenue in fiscal 2025?
Athira Pharma (ATHA) reported revenue of $0 for fiscal 2025.
What is Athira Pharma's annual revenue history?
Athira Pharma's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Athira Pharma's net income in fiscal 2025?
Athira Pharma reported net income of -$105.6M for fiscal 2025.
What was Athira Pharma's earnings per share (EPS) in fiscal 2025?
Athira Pharma's diluted EPS was -$24.70 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Athira Pharma generate in fiscal 2025?
Athira Pharma generated -$45.8M of free cash flow in fiscal 2025.
What was Athira Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Athira Pharma reported revenue of $0.
How many shares of Athira Pharma are outstanding?
Athira Pharma reported a weighted average of 23.7 million basic shares outstanding in 2026 Q2.
What is Athira Pharma's market cap?
Based on its latest closing price, Athira Pharma (ATHA) has a market capitalization of about $152.6M.
When does Athira Pharma's fiscal year end?
Athira Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Athira Pharma headquartered?
Athira Pharma lists its business address in Bothell, Washington in its SEC filings.
Athira Pharma Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →